Symbiotec Pharmalab IPO

Incorporated in 2002, Symbiotec Pharmalab Limited is a research-driven pharmaceutical and biotechnology company focused on the development and manufacturing of active pharmaceutical ingredients (APIs), fermentation-based products, nutritional ingredients and specialty pharmaceutical products. 

With more than three decades of industry experience, Symbiotec Pharmalab has grown from a laboratory-scale manufacturer of steroidal hormone APIs in 1995 into a large-scale, backward-integrated pharmaceutical manufacturing platform.

As of June 30, 2025, Symbiotec operated two industrial-scale API manufacturing facilities with maximum chemical synthesis capacity of 584.67 MT and fermentation capacity of 300 KL. Subsequently, the company commissioned two additional facilities, taking its aggregate fermentation capacity to 700 KL and adding complex injectable capacity of 20 million vials per annum. 

As of June 30, 2025, Symbiotec served more than 200 customers across over 40 countries, including pharmaceutical companies in North America, Europe and Asia. Its customer base comprised more than 50 domestic customers and 150 export customers. 

The company’s manufacturing facilities have received approvals and accreditations from regulatory authorities including the US FDA, EU-GMP and the Ministry of Food and Drug Safety, Korea, among others. 

As of June 30, 2025, it operated three dedicated R&D centres in Indore focused on organic chemistry, biotechnology and complex injectables. 

Symbiotec places emphasis on sustainable manufacturing, with initiatives including flow chemistry, renewable energy utilisation and zero-liquid-discharge systems.